|Videos|June 23, 2020

Patrick Soon Shiong, MD: Justice & American Values During the Coronavirus Pandemic

Patrick Soon-Shiong, MD, CEO of ImmunityBio, discusses the pandemic as a unique moment in world & American history.

Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, discusses the pandemic as a unique moment in world & American history.

Part 1: SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.

Part 2: Goals of Operation Warp Speed

Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, describes goals and expectations for the accelerated coronavirus vaccine program Operation Warp Speed.

Related Coverage: Racial Disparities in Coronavirus Incidence, Knowledge, and Exposure

A recent US survey showed African American men were more likely to know someone infected by COVID-19, had a greater knowledge disparity of how the virus spread, and were more likely to be exposed to the virus.

Marcella Alsan, MD, MPH, PhD, associate professor of medicine, Stanford University, led a team of investigators who developed the survey and analyzed the results. The survey’s findings were reported in JAMA.

Read the full story.

Related Coverage: Inadequate Insurance Coverage Drives COVID-19 Racial & Economic Disparities

While calls for racial justice have reached a groundswell in recent weeks, it is clear from the COVID-19 pandemic and response that many health care inequities tied to both race and cross-racial economic factors are a long way from resolution.

According to Johns Hopkins University as of June 12, roughly 2,029,037 individuals have been confirmed to have contracted SARS-CoV-2. Even outside the most concerning pools of individuals at high-risk for severe infection, the outbreak carries risks for substantial financial consequences for any American hospitalized or kept out of work.

Read the full story.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.